Adding celecoxib to levodopa/carbidopa for Parkinson's disease
Official title: Evaluating Safety and Efficacy of Celecoxib in Patients With PD.
Run by Tanta University · NCT07246278 · Data updated 2026-11-12
This trial will see if giving celecoxib alongside levodopa/carbidopa helps people with Parkinson's disease by lowering inflammation and improving motor symptoms.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Status | Recruiting |
| Started | November 20, 2025 |
| Main results expected | November 20, 2026 |
| Study ends | November 28, 2026 |
| Registry record updated | December 5, 2025 |
| Trial ID | NCT07246278 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a clinical diagnosis of Parkinson's disease (per UPDRS) who are not pregnant or breastfeeding, do not have significant liver or kidney dysfunction, are not using other anti-inflammatory drugs, and have no allergy to celecoxib or sulfonamides.
✕Probably not a fit
People who are pregnant or breastfeeding, have severe liver or kidney disease, are allergic to celecoxib/sulfonamides, or are currently taking other anti-inflammatory medications would not be eligible and are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1/2 interventional trial testing celecoxib 200 mg as an add-on to standard levodopa/carbidopa therapy in adults with Parkinson's disease. Participants who meet eligibility will receive celecoxib in addition to their usual dopaminergic medication and will be followed for safety, inflammatory biomarkers (including HMGB1), and clinical motor outcomes. Key exclusions include pregnancy, breastfeeding, significant liver or kidney dysfunction, sulfonamide allergy, current use of other anti-inflammatory drugs, and substance abuse. The trial is conducted at Tanta University with regular clinic visits and laboratory monitoring.
Why it matters
Potential benefit: If successful, adding celecoxib could reduce neuroinflammation and lead to improved motor symptoms or slower symptom progression in people with Parkinson's disease.
How similar studies have gone: Preclinical work and some small clinical studies suggest anti-inflammatory approaches may help in Parkinson's disease, but using celecoxib as an add-on in this specific context is relatively novel with limited prior clinical evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * Both male and female will be included. * Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale. Exclusion Criteria: * Breast feeding * Patients with significant liver and kidney function abnormalities. * Alcohol and / or drug abusers. * Patients with known allergy to the study medications * Patients with known allergy to sulfonamides (cross hypersensitivity with celecoxib). * Pregnant women and women with planned pregnancy. * Patients who are currently using other anti-inflammatory drugs.
Where it's running
-
Tanta Unuversity
Tanta, Egypt Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.